ולטרקס טבליות 500 מג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ixtrih issa

Ingredjent attiv:

VALACICLOVIR AS HYDROCHLORIDE

Disponibbli minn:

GLAXO SMITH KLINE (ISRAEL) LTD

Kodiċi ATC:

J05AB11

Għamla farmaċewtika:

טבליות מצופות פילם

Kompożizzjoni:

VALACICLOVIR AS HYDROCHLORIDE 500 MG

Rotta amministrattiva:

פומי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

GLAXO WELLCOME SA, SPAIN

Grupp terapewtiku:

VALACICLOVIR

Żona terapewtika:

VALACICLOVIR

Indikazzjonijiet terapewtiċi:

Valtrex is indicated for the treatment of herpes zoster (shingles) in immunocopotent adults.Valtrex accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. The efficacy of valaciclovir in immunocompromised patients has not been established. Valtrex is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. Valtrex is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). Prophylaxis of cytomegalovirus infection and disease, following organ transplantation. For the treatment of cold sores (herpes labialis).

Sommarju tal-prodott:

התרופה תינתן למניעת מחלת CMV במושתלי איברים

Data ta 'l-awtorizzazzjoni:

2021-02-28

Fuljett ta 'informazzjoni

                                " (
)
-
1986
500
"
500
(
) "
VALACICLOVIR (AS HYDROCHLORIDE)
500
MG
6
.
.
.
,
.
.
.
.
1
.
?
)
HSV
) ,(
VZV
(
-
)
CMV
.(
:
•
.
•
VZV
)
ophthalmic zoster
(
.
•
)
HSV
(
)
(
.
.
•
)
HSV
. (
•
CMV
.
:
.
2
.
:
()
)
6
.(
: ,
•
.
•
.
•
65
.
•
.
-
:
)
DRESS
(
.
DRESS
,
. (
)
← ,
. , . , , .
. / , , , . ,
: .
,
,
, ,
. , , , , ,
.
,
,
,
.
.
)
.(
3
.
?
.
.
.
:
)
zoster
s
Herpe
(
•
1,000
)
"
500
,("
.
•
.
)
sores
Cold
)
(
12
(
•
2,000
) "
500
. ,("
•
12
)
6
. (
•
. (
)
HSV
)
12
(
•
500
. ,"
•
.
3
5
.
HSV
)
12
(
•
500
.
,"
•
.
CMV
)
-
)
(
12
(
•
2,000
) "
500
,("
.
•
6
.
•
.
•
90
,
.
:
•
65
.
•
.
•
.
←
.
.
:
•
.
•
.
•
.//
•
.
•
.
65
.
.
.
.
,
.
,
, , ,
. ,
,
,
,
.
, .
,
. ,
.
. ! .
.
. ,
4
.
,
.
. .
:
←
:
.
.(
)
:
•
,
•
()
, , ,
•
.
) ,
.
DRESS
(
. ,
:
)
COMMON
VERY
(
-
:
•
)
COMMON
(
-
-
10
-
1
100
:
•
•
•
•
•
(
)
•
•
)
UNCOMMON
(
-
-
10
-
1
1,000
:
•
•
()
•
•
•
,
,
,
-
8
.
.
:
•
()
•
•
, ,
(
)
•
( )
•
()
:
•
(
)
•
(
)
•
)
RE
RA
(
-
-
10
-
1
10,000
:
•
()
•
() ,
•
()
•
()
•
()
•
()
,
,
,
-
8
.
.
:
•
)
(
:
•
DRESS
,
,
,
,()
,
.
2
.
•
(tubulointerstitial nephritis) ,
. ,
"
"
)
www.health.gov.il
" ,
(
:
https://sideeffects.health.gov.il/
5
.
?
•
!
.
/
.
•
)
exp. date
(
.
.
•
-
C
30°
.
6
.
• ,
:
Microcrystalline cellulose
Crospovidone
Povidone ,K90
White Colour Concentrate YS-
18043
-
1
(Hypromellose, Titanium dioxide, Polysorbate 80, Polyethylene Glycol
400)
Magnesium stearate
Colloidal Anhydrous Silica
Carnauba wax.
•
:
.
500
"
2
,
10
42
.
-
"
GX CF1
"
.
.
•
:
S.A.
.
, ,
•
:
' ," (
)
25
. ,
•
:
100-39-28426-00
.
,
.
,
.
GSK
.
©
2023
GSK
.
2023
.
Val PT v9A
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ingliż 07-06-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ingliż 04-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Għarbi 07-06-2023